Report a data issue, formatting problem, or request follow-up. Our team responds within one business day.
Be the first to review this report.
Viral vectors carry genetic material into cells by exploiting the molecular mechanisms by which viruses transmit their genomes to other cells for infection.It can occur in vivo or in vitro.Plasmid carriers are plasmids artificially constructed on the basis of natural plasmids to adapt to laboratory operations.In recent years, global viral vector and plasmid DNA manufacturing has developed rapidly, with a compound growth rate of about 28% during 2018-2018.In 2018, global sales of viral vector and plasmid DNA production reached $381 million.In 2018, China accounted for about 4% of global sales.In the next five years, the production of viral vectors and plasmid DNA products in China will continue to grow rapidly.Viral vector and plasmid DNA manufacturing are mainly divided into viral vector manufacturing and plasmid DNA manufacturing, among which viral vector manufacturing accounts for the largest proportion, accounting for nearly 38% of the total market in 2018.Viral vector and plasmid DNA manufacturing is mainly used for drug development and production of cancer, genetic diseases, viral infections and other diseases, among which cancer is the main application field, accounting for 35% in 2018.The market is highly competitive.Brammer Bio, Oxford BioMedica, Cobra Biologics, FinVector and Lonza are major suppliers.They have mastered key technologies and patents, and they have a fixed customer base. They have established a monopoly in the market.Gene therapy technology innovation and clinical trials have mushroomed in recent years, and a number of gene therapy projects have been approved for marketing in the United States, the European Union, China and other countries.The target of gene therapy has also been gradually expanded from single gene genetic diseases to malignant tumors, infectious diseases, cardiovascular diseases, autoimmune diseases, metabolic diseases and other major diseases.
Global Viral Vector and Plasmid DNA key players include BioReliance, Oxford BioMedica, UniQure, Cobra Biologics, etc. Global top four manufacturers hold a share over 45%.
North America is the largest market, with a share about 50%, followed by Europe, and Asia-Pacific, both have a share over 40 percent.
In terms of product, Viral Vectors is the largest segment, with a share about 80%. And in terms of application, the largest application is Cancers, followed by Inherited Disorders, Viral Infections, etc.
This report provides an overview of the global Viral Vector and Plasmid DNA market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Viral Vector and Plasmid DNA and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Viral Vector and Plasmid DNA revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Viral Vector and Plasmid DNA market.
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Viral Vector and Plasmid DNA industry.
Chapter 3: Detailed analysis of Viral Vector and Plasmid DNA company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Viral Vector and Plasmid DNA in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Viral Vector and Plasmid DNA in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
You may also be interested in
